Clinical trials with HER2-positive patients with advanced NSCLC failed to improve treatment outcome for most of the patients in the trial, although a small percentage, in whom HER2 was found to be positive by fluorescence in situ hybridisation (FISH), responded to treatment. Here, ERBB2 is linked to non-small cell lung carcinoma.